Insmed

NASDAQ: INSM · Real-Time Price · USD
72.41
-0.23 (-0.32%)
At close: May 02, 2025, 3:59 PM
72.30
-0.15%
After-hours: May 02, 2025, 04:05 PM EDT
-0.32%
Bid 71.5
Market Cap 13.17B
Revenue (ttm) 363.71M
Net Income (ttm) -913.77M
EPS (ttm) -5.57
PE Ratio (ttm) -13
Forward PE -19.05
Analyst Buy
Ask 73.18
Volume 1,221,825
Avg. Volume (20D) 2,165,470
Open 73.03
Previous Close 72.64
Day's Range 71.96 - 73.31
52-Week Range 21.92 - 84.91
Beta 1.07

About INSM

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutr...

Sector Healthcare
IPO Date Jun 1, 2000
Employees 1,271
Stock Exchange NASDAQ
Ticker Symbol INSM
Full Company Profile

Analyst Forecast

According to 16 analyst ratings, the average rating for INSM stock is "Buy." The 12-month stock price forecast is $97, which is an increase of 33.96% from the latest price.

Stock Forecasts

Next Earnings Release

Insmed is scheduled to release its earnings on May 8, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
8 months ago
+1.16%
Insmed shares are trading lower after the company ... Unlock content with Pro Subscription
10 months ago
Insmed shares are trading higher after B of A Securities maintained a Buy rating on the stock.